LQDA Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -1229.71% compared to Liquidia's net margin of --. Liquidia's return on equity of -165.38% beat Armata Pharmaceuticals's return on equity of --.

Liquidia has a consensus price target of $30.30, signalling upside risk potential of 108.39%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $9.00 which suggests that it could grow by 275%. Given that Armata Pharmaceuticals has higher upside potential than Liquidia, analysts believe Armata Pharmaceuticals is more attractive than Liquidia.

Liquidia has a beta of -0.012, which suggesting that the stock is 101.152% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.224%.

Liquidia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Liquidia quarterly revenues are $3.1M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Liquidia's net income of -$38.4M is lower than Armata Pharmaceuticals's net income of -$6.5M. Notably, Liquidia's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia is 83.42x versus 1,002.10x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Insmed has a net margin of -1229.71% compared to Liquidia's net margin of -276.42%. Liquidia's return on equity of -165.38% beat Insmed's return on equity of -1146.32%.

Liquidia has a consensus price target of $30.30, signalling upside risk potential of 108.39%. On the other hand Insmed has an analysts' consensus of $113.55 which suggests that it could grow by 10.72%. Given that Liquidia has higher upside potential than Insmed, analysts believe Liquidia is more attractive than Insmed.

Liquidia has a beta of -0.012, which suggesting that the stock is 101.152% less volatile than S&P 500. In comparison Insmed has a beta of 0.902, suggesting its less volatile than the S&P 500 by 9.818%.

Liquidia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

Liquidia quarterly revenues are $3.1M, which are smaller than Insmed quarterly revenues of $92.8M. Liquidia's net income of -$38.4M is higher than Insmed's net income of -$256.6M. Notably, Liquidia's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia is 83.42x versus 46.32x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -1229.71% compared to Liquidia's net margin of -35.79%. Liquidia's return on equity of -165.38% beat Protalix BioTherapeutics's return on equity of 10.9%.

Liquidia has a consensus price target of $30.30, signalling upside risk potential of 108.39%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 865.52%. Given that Protalix BioTherapeutics has higher upside potential than Liquidia, analysts believe Protalix BioTherapeutics is more attractive than Liquidia.

Liquidia has a beta of -0.012, which suggesting that the stock is 101.152% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

Liquidia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Liquidia quarterly revenues are $3.1M, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. Liquidia's net income of -$38.4M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Liquidia's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 36.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia is 83.42x versus 2.03x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics has a net margin of -1229.71% compared to Liquidia's net margin of 40.56%. Liquidia's return on equity of -165.38% beat United Therapeutics's return on equity of 19.92%.

Liquidia has a consensus price target of $30.30, signalling upside risk potential of 108.39%. On the other hand United Therapeutics has an analysts' consensus of $377.01 which suggests that it could grow by 29.11%. Given that Liquidia has higher upside potential than United Therapeutics, analysts believe Liquidia is more attractive than United Therapeutics.

Liquidia has a beta of -0.012, which suggesting that the stock is 101.152% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.534, suggesting its less volatile than the S&P 500 by 46.629%.

Liquidia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

Liquidia quarterly revenues are $3.1M, which are smaller than United Therapeutics quarterly revenues of $794.4M. Liquidia's net income of -$38.4M is lower than United Therapeutics's net income of $322.2M. Notably, Liquidia's price-to-earnings ratio is -- while United Therapeutics's PE ratio is 11.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia is 83.42x versus 4.71x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.